Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-866-8548
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$129.16 million
Profitability
Miscellaneous
Employees179
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions
What is Denali Therapeutics' stock symbol?
Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."
How were Denali Therapeutics' earnings last quarter?
Denali Therapeutics Inc (NASDAQ:DNLI) issued its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.15. The company had revenue of $4.20 million for the quarter, compared to analysts' expectations of $4.52 million. Denali Therapeutics had a negative net margin of 40.78% and a negative return on equity of 11.03%. View Denali Therapeutics' Earnings History.
When is Denali Therapeutics' next earnings date?
What price target have analysts set for DNLI?
6 brokers have issued 12-month target prices for Denali Therapeutics' stock. Their predictions range from $25.00 to $35.00. On average, they expect Denali Therapeutics' share price to reach $29.3333 in the next twelve months. This suggests a possible upside of 54.3% from the stock's current price. View Analyst Price Targets for Denali Therapeutics.
What is the consensus analysts' recommendation for Denali Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Denali Therapeutics.
What are Wall Street analysts saying about Denali Therapeutics stock?
Here are some recent quotes from research analysts about Denali Therapeutics stock:
- 1. HC Wainwright analysts commented, "We include in our valuation given their clinical stage, and view DNL310 as a free call option at this point. Our 12-month price target of $28/share is based on an equally weighted composite of (a) $29/share, as a 35x multiple of taxed and diluted FY34 GAAP EPS of $8.62 discounted back to and (b) an NPV of $28/ share (discount rate 12.0%, growth rate 2.5%). The assumptions are in-line with the expected PE multiple and discount rate of an early development-stage biopharmaceutial company." (8/8/2019)
- 2. According to Zacks Investment Research, "Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO, United States. " (8/7/2019)
Has Denali Therapeutics been receiving favorable news coverage?
News coverage about DNLI stock has been trending negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Denali Therapeutics earned a news impact score of -2.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Denali Therapeutics.
Who are some of Denali Therapeutics' key competitors?
Some companies that are related to Denali Therapeutics include bluebird bio (BLUE), Moderna (MRNA), Adaptive Biotechnologies (ADPT), argenx (ARGX), Repligen (RGEN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Regenxbio (RGNX) and Audentes Therapeutics (BOLD).
What other stocks do shareholders of Denali Therapeutics own?
Who are Denali Therapeutics' key executives?
Denali Therapeutics' management team includes the folowing people:
- Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 43)
- Mr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 46)
- Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 59)
- Mr. Steve E. Krognes, CFO & Treasurer (Age 50)
- Dr. Carole Ho, Chief Medical Officer & Head of Devel. (Age 46)
When did Denali Therapeutics IPO?
(DNLI) raised $149 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.
Who are Denali Therapeutics' major shareholders?
Denali Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (7.76%), Vanguard Group Inc. (6.06%), BlackRock Inc. (5.38%), Wasatch Advisors Inc. (1.04%), Pictet Asset Management Ltd. (0.77%) and Pictet Asset Management Ltd. (0.77%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Carole Ho, Douglas K Bratton and Ryan J Watts. View Institutional Ownership Trends for Denali Therapeutics.
Which major investors are selling Denali Therapeutics stock?
DNLI stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Allianz Asset Management GmbH, Pier 88 Investment Partners LLC, Zurcher Kantonalbank Zurich Cantonalbank, BNP Paribas Arbitrage SA, Invesco Ltd., Bank of America Corp DE and Bank of New York Mellon Corp. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho and Ryan J Watts. View Insider Buying and Selling for Denali Therapeutics.
Which major investors are buying Denali Therapeutics stock?
DNLI stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Pictet Asset Management Ltd., Pictet Asset Management Ltd., BlackRock Inc., Wasatch Advisors Inc., Nuveen Asset Management LLC, Citadel Advisors LLC and Balyasny Asset Management LLC. View Insider Buying and Selling for Denali Therapeutics.
How do I buy shares of Denali Therapeutics?
Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Denali Therapeutics' stock price today?
One share of DNLI stock can currently be purchased for approximately $19.01.
How big of a company is Denali Therapeutics?
Denali Therapeutics has a market capitalization of $1.82 billion and generates $129.16 million in revenue each year. The company earns $-36,240,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Denali Therapeutics employs 179 workers across the globe.View Additional Information About Denali Therapeutics.
What is Denali Therapeutics' official website?
How can I contact Denali Therapeutics?
Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.
MarketBeat Community Rating for Denali Therapeutics (NASDAQ DNLI)
MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote "Outperform" if you believe DNLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
